申请人:Sumitomo Pharmaceuticals Company, Limited
公开号:EP1238971A1
公开(公告)日:2002-09-11
A compound represented by the following formula:
wherein R is a substituted or unsubstituted benzene ring, a fused polycyclic hydrocarbon ring which is substituted or unsubstituted, a monocyclic heterocyclic ring which is substituted or unsubstituted, a polycyclic heterocyclic ring which is substituted or unsubstituted, A and E are independently a single bond, a lower alkylene group or the like, G is a single bond, an oxygen atom or the like, and Y is a -SO3H group or the like, a prodrug of said compound, or a pharmaceutically acceptable salt of said compound or prodrug is useful as a therapeutic or prophylactic agent for diseases caused by the acceleration of the sodium/proton exchange transport system.
下式所代表的化合物:
其中 R 是取代或未取代的苯环、取代或未取代的融合多环烃环、取代或未取代的单环杂环、取代或未取代的多环杂环,A 和 E 独立地为单键、低级亚烷基或类似基团、G是单键、氧原子或类似物,Y是-SO3H基团或类似物,所述化合物的原药或所述化合物或原药的药学上可接受的盐可用作钠/质子交换转运系统加速所致疾病的治疗剂或预防剂。